Patient ID: **10822** 

Specimen ID: 163-307-0402-0

DOB: **09/08/1984** 

Age: **40** Sex: **Female** 

### **Patient Report**

Account Number: **16015670**Ordering Physician: **J FOUCHER** 



Date Collected: **06/10/2025** 

Date Received: 06/12/2025

Date Reported: **06/17/2025** 

Fasting: Yes

Ordered Items: NMR LipoProfile+Lipids; CBC With Differential/Platelet; Comp. Metabolic Panel (14); p-tau217; Beta Amyloid 42/40 Ratio; C-Reactive Protein, Cardiac; Cortisol; DHEA-Sulfate; Folate (Folic Acid), Serum; Hemoglobin A1c; Homocyst(e)ine; IGF-1; Thyroxine (T4) Free, Direct; TSH; Vitamin D, 25-Hydroxy; Uric Acid; Apolipoprotein B; Insulin; Vitamin B12

Date Collected: 06/10/2025

## NMR LipoProfile+Lipids

Test	Current Resul	t and Flag	Previous Result and Date		Units	Reference Interva
LDL Particle Number <sup>01</sup>						
LDL-P <sup>A, 01</sup>	1258	High	961	02/27/2025 Low Moderate Borderline-High High Very High	nmol/L < 1000 1000 - 1299 1300 - 1599 1600 - 2000 > 2000	<1000
Lipids 01						
LDL-C (NIH Calc) 01	113	High	111	02/27/2025 Optimal Above optimal Borderline High Very high	mg/dL < 100 100 - 129 130 - 159 160 - 189 > 189	0-99
HDL-C A, 01	69		56	02/27/2025	mg/dL	>39
Triglycerides A, 01	40		69	02/27/2025	mg/dL	0-149
Cholesterol, Total <sup>A, 01</sup>	190		180	02/27/2025	mg/dL	100-199
LDL and HDL Particles 01						
HDL-P (Total) <sup>A,01</sup>	31.2		26.3	02/27/2025	umol/L	>=30.5
Small LDL-P A, 01	424		249	02/27/2025	nmol/L	<=527
LDL Size A, 01	20.9		21.6	02/27/2025	nm	>20.5
	LDL AND HDL PA HDL-P (total) Small LDL-P LDL Size <-	ARTICLES Per High >34.9 Low <117 Large (Pattern	NCENTRATION CVD Risk rcentile in 75th 34.9 25th 117	AND SIZE Higher CVD Risk Reference Populat 50th 25th Lo 30.5 26.7 <2 50th 75th H:	tion bw 26.7 igh 339 )->	
Comment: 01	Small LDL-P and LDL-P is taken :		associated	with CVD risk, bu	ut not after	
Insulin Resistance Score						
LP-IR Score A, 01	<25 INSULIN RESISTA <insulin s<br="">Perco Insulin Resista</insulin>	Sensitive : entile in Refe	<25 Insulin Resi erence Popul			<=45

labcorp

Date Created and Stored  $\,06/17/25\,0311\,ET\,$  Final Report  $\,$  Page 1 of 8

Patient ID: **10822** 

Specimen ID: 163-307-0402-0

DOB: **09/08/1984** 

Age: **40** Sex: **Female** 

## **Patient Report**

Account Number: **16015670**Ordering Physician: **J FOUCHER** 



Date Collected: 06/10/2025

## NMR LipoProfile+Lipids (Cont.)

LP-IR Score Low 25th 50th 75th High <27 27 45 63 >63

Comment: 01

LP-IR Score is inaccurate if patient is non-fasting. The LP-IR score is a laboratory developed index that has been associated with insulin resistance and diabetes risk and should be used as one component of a physician's clinical assessment.

## **CBC With Differential/Platelet**

	Test	Current Resu	lt and Flag	Previous Re	sult and Date	Units	Reference Interval
	WBC 02	6.2		7.0	10/24/2024	x10E3/uL	3.4-10.8
_	RBC 02	5.62	High	4.96	10/24/2024	x10E6/uL	3.77-5.28
	Hemoglobin 02	14.4		12.9	10/24/2024	g/dL	11.1-15.9
_	Hematocrit 02	47.9	High	43.0	02/27/2025	%	34.0-46.6
	MCV <sup>02</sup>	85		85	10/24/2024	fL	79-97
<b>V</b>	MCH 02	25.6	Low	26.0	10/24/2024	pg	26.6-33.0
<b>V</b>	MCHC 02	30.1	Low	30.6	10/24/2024	g/dL	31.5-35.7
	RDW 02	12.6		13.1	10/24/2024	%	11.7-15.4
	Platelets 02	301		254	10/24/2024	x10E3/uL	150-450
	Neutrophils 02	52		52	10/24/2024	%	Not Estab.
	Lymphs 02	38		35	10/24/2024	%	Not Estab.
	Monocytes 02	7		8	10/24/2024	%	Not Estab.
	Eos 02	2		4	10/24/2024	%	Not Estab.
	Basos 02	1		1	10/24/2024	%	Not Estab.
	Neutrophils (Absolute) 02	3.2		3.7	10/24/2024	x10E3/uL	1.4-7.0
	Lymphs (Absolute) 02	2.4		2.4	10/24/2024	x10E3/uL	0.7-3.1
	Monocytes(Absolute) 02	0.4		0.6	10/24/2024	x10E3/uL	0.1-0.9
	Eos (Absolute) 02	0.1		0.3	10/24/2024	x10E3/uL	0.0-0.4
	Baso (Absolute) 02	0.1		0.1	10/24/2024	x10E3/uL	0.0-0.2
	Immature Granulocytes 02	0		0	10/24/2024	%	Not Estab.
	Immature Grans (Abs) 02	0.0		0.0	10/24/2024	x10E3/uL	0.0-0.1

### Comp. Metabolic Panel (14)

Test	Current Resu	ılt and Flag	Previous Result and Date		Units	Reference Interval
▲ Glucose <sup>02</sup>	101	High	95	02/27/2025	mg/dL	70-99
BUN 02	15		15	02/27/2025	mg/dL	6-24
Creatinine 02	0.67		0.74	02/27/2025	mg/dL	0.57-1.00
eGFR	113		105	02/27/2025	mL/min/1.73	>59
BUN/Creatinine Ratio	22		20	02/27/2025		9-23
Sodium <sup>02</sup>	136		136	02/27/2025	mmol/L	134-144
Potassium 02	4.3		4.9	02/27/2025	mmol/L	3.5-5.2
Chloride 02	100		100	02/27/2025	mmol/L	96-106
▼ Carbon Dioxide, Total 02	19	Low	24	02/27/2025	mmol/L	20-29
Calcium <sup>02</sup>	9.4		9.9	02/27/2025	mg/dL	8.7-10.2
Protein, Total <sup>02</sup>	7.2		7.4	02/27/2025	g/dL	6.0-8.5

### labcorp

Date Created and Stored  $\,06/17/25\,0311\,ET\,$  Final Report  $\,$  Page 2 of 8

Patient ID: **10822** 

Specimen ID: 163-307-0402-0

DOB: **09/08/1984** 

Age: **40** Sex: **Female** 

## **Patient Report**

Account Number: **16015670**Ordering Physician: **J FOUCHER** 



Date Collected: 06/10/2025

## Comp. Metabolic Panel (14) (Cont.)

Albumin 02	4.4	4.6	02/27/2025	g/dL	3.9-4.9
Globulin, Total	2.8	2.8	02/27/2025	g/dL	1.5-4.5
Bilirubin, Total 02	0.2	0.4	02/27/2025	mg/dL	0.0-1.2
Alkaline Phosphatase 02	54	57	02/27/2025	IU/L	44-121
AST (SGOT) 02	17	21	02/27/2025	IU/L	0-40
ALT (SGPT) 02	14	24	02/27/2025	IU/L	0-32

### p-tau217

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
p-tau217 <sup>A,03</sup>	cohort characterized with am is a reported surrogate mark used to facilitate biologica (1). p-tau217 has also been patients on anti-amyloid the Test performed by Fujire immunoassay (CLEIA). Values	bio Lumipulse chemiluminesce obtained with different metho lidated limit of quantificat:	alue of >0.18 y, and can be r's disease onitor  nt enzyme ods cannot be	0.00-0.18
Footnotes <sup>03</sup>	Phosphorylated Tau 217 Immun JAMA neurology (2024). 2. Ashton, Nicholas J., et a and p-tau217 for Alzheimer's Nature medicine 28.12 (2022) 3. Pontecorvo MJ, Lu M, Burn Treatment With Exploratory P Alzheimer Disease: A Seconda	1. "Diagnostic Accuracy of a oassay for Alzheimer Disease 1. "Differential roles of A42 trial selection and disease: 2555-2562. ham SC, et al. "Association of lasma Biomarkers in Early Syry Analysis of the TRAILBLAZI JAMA Neurol. 2022;79(12):1250	Pathology."  2/40, p-tau231 monitoring."  of Donanemab mptomatic ER-ALZ	

# Beta Amyloid 42/40 Ratio

Test	Current Result and Flag	<b>Previous Result and Date</b>	Units	Reference Interva		
Beta-amyloid 42/40 Ratio B, 01	0.118					
Beta-amyloid 42 B, 01	14.75		pg/mL			
Beta-amyloid 40 B, 01	124.48		pg/mL			
	diagnosed with Alzheimer's D suggest a lower probability testing of Beta Amyloid 42 a comparable effectiveness to testing and amyloid positron When assessing the risk of A for mild cognitive impairmen to consider various factors nutritional deficiency bioma neurological, and neuropsych	of a patient being clinical disease (AD), while values ab of AD diagnosis. Precise play and Beta Amyloid 40 has demon traditional cerebrospinal flay emission tomography (PET) so AD pathology as the underlying at (MCI) or dementia, it is it such as medical and family harkers, neuroimaging, and phynological examinations.	ove 0.102 sma strated uid cans. g cause mportant istory, sical,			

labcorp

Date Created and Stored  $\,$  06/17/25 0311 ET  $\,$  Final Report  $\,$  Page 3 of 8  $\,$ 

Patient ID: **10822** 

Specimen ID: **163-307-0402-0** 

DOB: **09/08/1984** 

Age: **40** Sex: **Female** 

## **Patient Report**

Account Number: **16015670**Ordering Physician: **J FOUCHER** 



Date Collected: 06/10/2025

## Beta Amyloid 42/40 Ratio (Cont.)

Values obtained with different methods cannot be used interchangeably.

C Dooctive	a Dratain	Cardiac
<b>C-Reactiv</b>	e Proteiii	, caruiac

Test	Current Result and Flag	Previous Result and Date			Units	Reference Interval
C-Reactive Protein, Cardiac 02	0.36		0.35	10/24/2024	mg/L	0.00-3.00
		Rela	tive Risk for	Future Cardiov	ascular Event	
				Low	<1.00	
				Average	1.00 - 3.00	
				High	>3.00	

#### Cortisol

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Cortisol 02	8.4	16.7 10/24/2024	ug/dL	6.2-19.4
		The reference interval and flat for an AM collection. If this lease use: Cortisol Pl		

#### **DHEA-Sulfate**

Test	Current Result and Flag		Previous Res	Previous Result and Date		Reference Interval
▲ DHEA-Sulfate 02	284.0	High	305.0	10/24/2024	ug/dL	57.3-279.2

## Folate (Folic Acid), Serum

Test		Current Result and Flag		Previous Result and Date		Units	Reference Interval
Folate (Folic Acid), Se	rum <sup>02</sup>	11.1		10.2	10/24/2024	ng/mL	>3.0
Note:02							

A serum folate concentration of less than 3.1  $\mbox{ng/mL}$  is considered to represent clinical deficiency.

## Hemoglobin A1c

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
Hemoglobin A1c 02	5.4	5.5	02/27/2025	%	4.8-5.6
Please Note: 02					
	D	c 1			

Prediabetes: 5.7 - 6.4

Diabetes: >6.4

Glycemic control for adults with diabetes: <7.0

## Homocyst(e)ine

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
Homocyst(e)ine 02	8.1	7.7	02/27/2025	umol/L	0.0-14.5

#### IGF-1

Test	Current Resu	ılt and Flag	Previous Result and Date		Units	Reference Interval
▲ Insulin-Like Growth Factor I 04	344	High	385	10/24/2024	ng/mL	79-259

### labcorp

Patient ID: 10822

Specimen ID: 163-307-0402-0

DOB: **09/08/1984** 

Age: **40** Sex: **Female** 

## **Patient Report**

Account Number: **16015670**Ordering Physician: **J FOUCHER** 



Date Collected: 06/10/2025

# Thyroxine (T4) Free, Direct

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
T4,Free(Direct) 02	1.28	1.19	10/24/2024	ng/dL	0.82-1.77

#### **TSH**

Test	Current Result and Flag	ult and Flag Previous Result and Date		Units	Reference Interval
TSH 02	1.240	2.480	10/24/2024	uIU/mL	0.450-4.500

## Vitamin D, 25-Hydroxy

Test	Current Result and Flag		Previous Result and Date		Reference Interval
Vitamin D, 25-Hydroxy 02	69.3	50.6	30.0-100.0		
	Vitamin D deficiency has bee Medicine and an Endocrine So level of serum 25-OH vitamin The Endocrine Society went o insufficiency as a level bet 1. IOM (Institute of Medicin intakes for calcium and D National Academies Press. 2. Holick MF, Binkley NC, Bi Evaluation, treatment, an deficiency: an Endocrine	ciety practice D less than 2 n to further d ween 21 and 29 e). 2010. Diet . Washington D schoff-Ferrari d prevention o	guideline as a 0 ng/mL (1,2). efine vitamin D ng/mL (2). ary reference C: The  HA, et al. f vitamin D	ng/mL	

### **Uric Acid**

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
Uric Acid 02	3.3	3.6	10/24/2024	mg/dL	2.6-6.2
	The	arangutic tar	ast for gout pati	ents: <6 0	

guideline. JCEM. 2011 Jul; 96(7):1911-30.

## **Apolipoprotein B**

Test	Current Result and Flag Previous Result and Date		Units	Reference Interval	
Apolipoprotein B <sup>02</sup>	77	92	02/27/2025 Desirable Borderline High High Very High	mg/dL < 90 90 - 99 100 - 130 >130	<90
	ŀ	ASCVD RISK CATEGORY Very High Risk High Risk Moderate Risk	APO B	TIC TARGET (mg/dL) eme risk <70)	

### Insulin

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
Insulin 02	10.1	13.5	02/27/2025	uIU/mL	2.6-24.9

## labcorp

Patient ID: 10822

Specimen ID: 163-307-0402-0

#### DOB: **09/08/1984**

Age: 40 Sex: Female

#### **Patient Report**

Account Number: 16015670 Ordering Physician: J FOUCHER



Date Collected: 06/10/2025

#### Vitamin B12

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
Vitamin B12 02	1082	>2000	02/27/2025	pg/mL	232-1245

#### Disclaimer

The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to match the result to the patient. Results from certain tests are excluded from the Previous Result display.

#### Icon Legend

#### Comments

A: This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.

B: This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.

#### Performing Labs

01: BN - Labcorp Burlington, 1447 York Court, Burlington, NC 27215-3361 Dir: Sanjai Nagendra, MD

02: SO - Labcorp San Diego, 13112 Evening Creek Dr So Ste 200, San Diego, CA 92128-4108 Dir: Earle Collum, Jr, MD

03: L9 - Monogram Biosciences Inc, 345 Oyster Point Blvd, S San Francisco, CA 94080-1913 Dir: Weidong Huang, MD

04: CETWE - Labcorp Phoenix, 5005 S 40th Street Ste 1200, Phoenix, AZ 85040-2969 Dir: Earle Collum, MD

For inquiries, the physician may contact Branch: 859-277-5341 Lab: 858-668-3700

**Patient Details** Vora, Akriti

Phone: 415-806-7996 Date of Birth: 09/08/1984

Age: 40 Sex: Female Patient ID: 10822

Alternate Patient ID: 10822

**Physician Details J FOUCHER** 

Wild Health 535 Wellington Way, Suite 330, Lexington,

KY, 40503

Phone: 859-439-0400 Account Number: 16015670

Physician ID: NPI: 1912433756 Specimen Details

Specimen ID: 163-307-0402-0

Control ID: 55853353

Alternate Control Number: 55853353 Date Collected: 06/10/2025 1443 Local Date Received: 06/12/2025 0000 ET

Date Entered: 06/12/2025 0807 ET Date Reported: 06/17/2025 0306 ET

Patient ID: 10822

Specimen ID: 163-307-0402-0

## DOB: **09/08/1984**

Age: **40** Sex: **Female** 


## **Patient Report**


Account Number: **16015670**Ordering Physician: **J FOUCHER** 



## **Historical Results & Insights**

Labcorp offers historical lab results data with easy-to-interpret visualizations to provide a more complete picture of a patient's lab history and improve patient care.





Patient ID: 10822

Specimen ID: 163-307-0402-0


DOB: **09/08/1984** 


Age: **40** Sex: **Female** 

## **Patient Report**

Account Number: **16015670**Ordering Physician: **J FOUCHER** 







#### **Cardiovascular Tests** Total TG HDL-C LDL-C LDL-P Date Chol. 190 40 1258 06/10/2025† 69 113 02/27/2025† 180 56 111 961 10/24/2024† 183 63 49 122 1357 Ref. Interval 100-199 0-149 >39 0-99 <1000 Units mg/dL mg/dL mg/dL mg/dL nmol/L † Fasting